Related Experiment Video
Updated: Mar 16, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy
Virginia Martínez-Marín1, Robert G Maki2
1Medical Oncology Service, Hospital Universitario La Paz, P° de la Castellana, 261, Madrid 28046, Spain.
Abstract:
The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review will help the reader understand the present standard of care to improve upon it in years to come.
Insights
This review discusses adjuvant therapy for gastrointestinal stromal tumors (GIST), focusing on the standard 3-year imatinib treatment for high-risk patients after surgery. It aims to clarify current care and guide future improvements in GIST management.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Gastrointestinal stromal tumors (GIST) management has evolved over 15 years.
- Three lines of systemic therapy exist for metastatic GIST: imatinib, sunitinib, and regorafenib.
Purpose of the Study:
- To review current issues and standards of care for adjuvant therapy in GIST.
- To provide a foundation for improving future adjuvant treatment strategies for GIST patients.
Main Methods:
- Literature review of GIST management and adjuvant therapy.
- Discussion of established treatment protocols and emerging considerations.
Main Results:
- Adjuvant therapy for GIST primarily involves 3-year imatinib treatment.
- This is recommended for patients with completely resected, higher-risk primary tumors.
Conclusions:
- Understanding the current standard of care for GIST adjuvant therapy is crucial.
- This knowledge is essential for optimizing treatment and improving patient outcomes in the future.
